公开(公告)号：EP1857549B1

公开(公告)日：2018-10-17

申请号：EP07008204.5

申请日：1999-03-19

申请人： Commonwealth Scientific and Industrial Research Organisation

发明人： Graham, Michael Wayne ,  Rice, Robert Norman ,  Waterhouse, Peter Michael ,  Wang, MingBo

IPC分类号： C12N15/11

CPC分类号： C12N15/113 ,  A01K2217/05 ,  A61K48/00 ,  C12N9/1051 ,  C12N9/127 ,  C12N9/503 ,  C12N15/111 ,  C12N15/1131 ,  C12N15/63 ,  C12N15/69 ,  C12N15/8216 ,  C12N15/8218 ,  C12N15/8283 ,  C12N15/85 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/10 ,  C12N2320/30 ,  C12N2330/30 ,  C12N2330/50 ,  C12N2330/51 ,  C12N2800/108 ,  C12N2830/00 ,  C12N2830/002 ,  C12N2830/15 ,  C12N2830/38 ,  C12N2830/42 ,  C12N2830/55 ,  C12N2830/60 ,  C12N2840/20

摘要： The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilises recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue, organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable or repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto are also provided.

公开(公告)号：EP3350337A1

公开(公告)日：2018-07-25

申请号：EP16847136.5

申请日：2016-09-13

申请人： Advaxis, Inc. ,  The Trustees of the University of Pennsylvania

发明人： WALLECHA, Anu ,  PATERSON, Yvonne

IPC分类号： C12P21/00 ,  C12N15/74 ,  C07K14/005 ,  C07K14/195 ,  A61K38/16

CPC分类号： C12N15/74 ,  A61K35/74 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/585 ,  A61K2039/6068 ,  A61K2039/6075 ,  A61K2039/892 ,  A61P35/00 ,  C07K14/005 ,  C07K14/025 ,  C07K14/195 ,  C07K19/00 ,  C07K2319/06 ,  C07K2319/55 ,  C12N1/20 ,  C12N5/00 ,  C12N2330/50 ,  C12N2511/00 ,  C12N2710/20022 ,  C12N2710/20033 ,  C12N2710/20034 ,  C12N2710/20043 ,  C12N2710/20051 ,  C12N2740/16234 ,  C12N2800/101 ,  C12P21/00

摘要： The present invention discloses a process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant Listeria comprising a human papilloma virus (HPV) antigen fused to a Listeriolysin O (LLO) protein fragment. The invention further discloses methods of using treating, protecting against, and inducing an immune response against cervical cancer comprising administration of the recombinant Listeria strain. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.

公开(公告)号：EP2841102B1

公开(公告)日：2018-06-27

申请号：EP13782196.3

申请日：2013-04-23

申请人： Ramot at Tel Aviv University, Ltd.

发明人： WERTHEIMER, Efrat

IPC分类号： A61K39/395 ,  A01K67/027 ,  C07K14/72 ,  C12N15/113 ,  C07K16/28

CPC分类号： C07K16/2869 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K31/713 ,  A61K38/1796 ,  A61K2039/505 ,  C07K14/72 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2330/50 ,  C12N2999/005 ,  C12N2310/531

摘要： The present invention generally concerns methods and compositions for treating skin hyperplasia and cancer.

公开(公告)号：EP2651286B1

公开(公告)日：2018-03-07

申请号：EP11849806.2

申请日：2011-11-07

申请人： Kimberly-Clark Worldwide, Inc.

发明人： MACDONALD, John, Gavin ,  KOH, CholWon ,  SA, InYoung ,  ABRAHAM, Jose, K. ,  RANGANATHAN, Sridhar

IPC分类号： A61B5/00 ,  A61B5/145

CPC分类号： C12N5/0678 ,  A61B5/082 ,  A61B5/4866 ,  A61B5/6867 ,  A61B5/6871 ,  A61B5/6873 ,  A61J15/00 ,  A61J15/0015 ,  A61J15/0084 ,  A61K35/39 ,  A61M2039/085 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2330/50 ,  C12N2500/25 ,  C12N2500/34 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/16 ,  C12N2501/42 ,  C12N2501/602 ,  C12N2501/65 ,  C12N2501/998

摘要： Systems and methods for monitoring nutritional uptake of an individual are disclosed. The method can include monitoring microflora intestinal gas concentration levels associated with a patient and adjusting the volume of nutrient provided by the patient with an artificial feeding device based at least in part on the microflora intestinal gas levels associated with the patient. A microflora intestinal gas sensor can be used to monitor the microflora intestinal gas associated with the patient. The microflora intestinal gas sensor can monitor the microflora intestinal gas in a patient's exhaled breath or in the patient's digestive tract. The microflora intestinal gas sensor be included as part of an enteral feeding system at the distal end or outside end of an enteral feeding tube. Systems and methods for monitoring nutritional uptake of an infant based on microflora intestinal gas levels associated with the infant are also disclosed.

公开(公告)号：EP3285811A1

公开(公告)日：2018-02-28

申请号：EP16721697

申请日：2016-04-21

申请人： ROUSSY INST GUSTAVE

发明人： PIROZHKOVA IRYNA ,  OGRYZKO VASILY

IPC分类号： A61K48/00 ,  A61K31/7088 ,  C07K14/47 ,  C12N15/113 ,  C12N15/86

CPC分类号： A61K31/7088 ,  A61K48/00 ,  C07K14/4705 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2330/50 ,  C12N2740/16043

摘要： The present invention relates to products and compositions as well as their therapeutic uses in human or veterinary medicine. In particular, the invention provides ZNF555 as a new therapeutic target for the prevention or treatment of a musculoskeletal disease in a subject. Particular embodiments include wherein the musculoskeletal disease is selected from Facioscapulohumeral Dystrophy (FSHD), a myopathy, musculoskeletal fibromatosis and muscular cachexia. Also disclosed is a method for identifying and selecting a compound inhibiting or decreasing the expression or activity of ZNF555, the method comprising a step of detecting and/or measuring the level of expression of ZNF555 or ANTI in a muscle cell in the presence of a test compound, wherein an absent or decreased expression of ZNF555 or ANTI in comparison with a control muscle cell that has not been exposed to or contacted with the test compound, is indicative of the capacity of said compound to inhibit or decrease the expression or activity of ZNF555 in said cell.

公开(公告)号：EP2434012B1

公开(公告)日：2017-12-13

申请号：EP10777759.1

申请日：2010-05-18

申请人： National Institute of Advanced Industrial Science and Technology

发明人： NAKANISHI, Mahito ,  NISHIMURA, Ken ,  OHTAKA, Manami ,  SANO, Masayuki

IPC分类号： C12N15/09 ,  C12N5/10 ,  C12N7/06 ,  C12N15/113 ,  C12N15/63 ,  C12N5/074 ,  C12N15/11 ,  C12N15/86 ,  C12N15/877 ,  C12N5/071

CPC分类号： C12N15/86 ,  C12N5/0696 ,  C12N15/111 ,  C12N15/1131 ,  C12N15/8775 ,  C12N15/8776 ,  C12N2310/14 ,  C12N2330/50 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2506/1307 ,  C12N2510/00 ,  C12N2760/18841 ,  C12N2760/18843 ,  C12N2760/18862

摘要： Cell reprogramming genes are loaded on a sustained expression-type Sendai virus vector free of an activity of incorporating exogenous genetic information into a chromosome. The genes are transfected into a normal differentiated cell via the vector, and expressed. Then, a vector genomic RNA including the genes is removed from the cell to establish an induced pluripotent stem cell. The Sendai virus vector makes it possible to generate an induced pluripotent stem cell having genomic information identical to that of a donor individual of the differentiated cell, in a significantly simple and efficient manner and in a safe manner with less risk of tumorigenic transformation. Thus, the Sendai virus vector can serve as an important tool for performing cell replacement therapies in a safe and efficient manner though the provision of useful induced pluripotent stem cells.

公开(公告)号：EP1230375B2

公开(公告)日：2016-10-26

申请号：EP00976188.3

申请日：2000-11-17

申请人： Cancer Research Technology Limited

发明人： Zernicka-Goetz, Magdelena Cambridge House ,  Wianny, Florence Cambridge House ,  Evans, Martin John Cambridge House ,  Glover, David Moore University of Cambridge,

IPC分类号： C12N15/63 ,  C12N15/11 ,  A61K31/713 ,  A01K67/027 ,  C12N5/10

CPC分类号： C12N15/113 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2217/058 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A61K38/00 ,  C12N15/111 ,  C12N15/1137 ,  C12N15/1138 ,  C12N15/63 ,  C12N15/8509 ,  C12N2015/8527 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2330/30 ,  C12N2330/50 ,  C12Y207/11001 ,  C12Y302/01031

公开(公告)号：EP2937417A1

公开(公告)日：2015-10-28

申请号：EP14166041.5

申请日：2014-04-25

申请人： Hochschule Biberach

发明人： Otte, Kerstin ,  Handrick, René ,  Fischer, Simon

IPC分类号： C12N15/11 ,  C12N15/113 ,  C12N15/67 ,  C12N15/85

CPC分类号： C12N15/113 ,  C12N15/111 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2330/50

摘要： The invention relates to a nucleic acid construct comprising at least two different regions, wherein the regions are selected of a first region encoding for at least one miRNA stimulating cellular production of a biomolecule in a cell, a second region encoding for at least one miRNA and/or miRNA-inhibitor suppressing cell death, and a third region encoding for at least one miRNA and/or miRNA-inhibitor regulating cell proliferation. The invention further relates to a cell comprising a respective nucleic acid construct and to a method for increasing the yield of a biomolecule produced by a cell cultured in vitro comprising at least two steps selected of stimulating cellular production of the biomolecule, reducing cell death, and regulating proliferation.

摘要翻译： 本发明涉及包含至少两个不同区域的核酸构建体，其中所述区域选自编码细胞中生物分子的至少一种miRNA的至少一种miRNA的第一区域，编码至少一种miRNA的第二区域和 或抑制细胞死亡的miRNA抑制剂，以及编码调节细胞增殖的至少一种miRNA和/或miRNA抑制剂的第三区域。 本发明还涉及包含相应的核酸构建体的细胞和用于提高由体外培养的细胞产生的生物分子的产率的方法，所述细胞包含选自刺激细胞生成生物分子，减少细胞死亡的至少两个步骤，和 调节增殖。

公开(公告)号：EP2434012A4

公开(公告)日：2013-11-06

申请号：EP10777759

申请日：2010-05-18

申请人： NAT INST OF ADVANCED IND SCIEN

发明人： NAKANISHI MAHITO ,  NISHIMURA KEN ,  OHTAKA MANAMI ,  SANO MASAYUKI

IPC分类号： C12N15/09 ,  C12N5/071 ,  C12N5/10 ,  C12N7/06 ,  C12N15/11 ,  C12N15/113 ,  C12N15/63 ,  C12N15/86 ,  C12N15/877

CPC分类号： C12N15/86 ,  C12N5/0696 ,  C12N15/111 ,  C12N15/1131 ,  C12N15/8775 ,  C12N15/8776 ,  C12N2310/14 ,  C12N2330/50 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2506/1307 ,  C12N2510/00 ,  C12N2760/18841 ,  C12N2760/18843 ,  C12N2760/18862

摘要： Cell reprogramming genes are loaded on a sustained expression-type Sendai virus vector free of an activity of incorporating exogenous genetic information into a chromosome. The genes are transfected into a normal differentiated cell via the vector, and expressed. Then, a vector genomic RNA including the genes is removed from the cell to establish an induced pluripotent stem cell. The Sendai virus vector makes it possible to generate an induced pluripotent stem cell having genomic information identical to that of a donor individual of the differentiated cell, in a significantly simple and efficient manner and in a safe manner with less risk of tumorigenic transformation. Thus, the Sendai virus vector can serve as an important tool for performing cell replacement therapies in a safe and efficient manner though the provision of useful induced pluripotent stem cells.

公开(公告)号：EP2488640A1

公开(公告)日：2012-08-22

申请号：EP10823705.8

申请日：2010-10-14

申请人： Nanyang Technological University

发明人： TAN, Nguan, Soon ,  CHONG, Han, Chung ,  TAN, Ming, Jie ,  HUANG, Royston

IPC分类号： C12N15/00 ,  C12N15/113 ,  C07K16/00 ,  A61P35/00 ,  A61K31/7088 ,  A61K39/395

CPC分类号： C12N15/1136 ,  A61K2039/505 ,  C07K16/22 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2330/50

摘要： The invention provides an antibody specific to the ANGPTL4 protein capable of neutralizing proliferation and methods of making and using the same. The antibody of the invention is further directed to the C terminal region of the protein and may be capable of neutralizing cell proliferation and treating cancer. The antibody may be monoclonal and or humanized antibody.